Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Should pseudomonas aeruginosa be the main target in bronchiectasis?

Fatma Isil Uzel, Sedat Altin, Seyma Özden, Derya Hirçin Çenger, Esin Tuncay
European Respiratory Journal 2016 48: PA4165; DOI: 10.1183/13993003.congress-2016.PA4165
Fatma Isil Uzel
1Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sedat Altin
1Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seyma Özden
1Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derya Hirçin Çenger
2Department of Infectious Diseases, Yedikule Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esin Tuncay
1Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: Bronchiectasis (BR) is a chronic lung disease with abnormally dilated bronchi. It can lead to frequent hospital admissions, ICU stays and eventually to death.

Aims and objectives: The aim of the study is to determine the microbiological and radiological distribution in BR patients and mortality associated with disease.

Methods: Patients with ICD10 code J47 of BR between 1.1.2003 to 31.12.2015 were retrospectively evaluated using database of our hospital. 251 out of 470 patients confirmed with HRCT were included. Clinical data, radiological localization, sputum culture, hospitalizations and mortality were investigated.

Results: 130 of 251 patients were female (51,7%).Mean age was 45 ±16 years. Sputum culture was available in 138 patients. Normal flora was detected in 65 (47%). P. aeruginosa was leading pathogen (38 patients-27,5%), followed by S.pneumoniae (9 patients-6,5%). In 28 (73,7%) of patients with P. aeruginosa , BR was bilateral. 29 (76,3%) of these patients were treated as inpatients, 8 of them had ICU admissions. 14 of 251 patients (5,6%) were dead in January 2016. The relation between smoking and mortality was statistically significant (p=0,024). P. aeruginosa and number of bacteria in sputum and ICU admissions were associated with mortality (p=0,0001). Higher number of lobes with BR were associated with mortality (p=0,036). Receiving COPD treatment was also associated with mortality (p=0,002).

Conclusions: P.aeruginosa is the most common pathogen in sputum of BR patients, causing hospital and ICU admissions and its presence is strongly associated with mortality. Attempts to eradicate P. Aeruginosa in BR patients should be encouraged to lower the 5,6% mortality in these patients.

  • Bronchiectasis
  • Infections
  • Imaging
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should pseudomonas aeruginosa be the main target in bronchiectasis?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Should pseudomonas aeruginosa be the main target in bronchiectasis?
Fatma Isil Uzel, Sedat Altin, Seyma Özden, Derya Hirçin Çenger, Esin Tuncay
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4165; DOI: 10.1183/13993003.congress-2016.PA4165

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Should pseudomonas aeruginosa be the main target in bronchiectasis?
Fatma Isil Uzel, Sedat Altin, Seyma Özden, Derya Hirçin Çenger, Esin Tuncay
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4165; DOI: 10.1183/13993003.congress-2016.PA4165
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical differences between emphysematous and non-emphysematous COPD
  • Clinical and epidemiological assessment of the regional program of vaccination for pneumococcal infections
  • Risk for adverse outcomes in asthma: Assess to impress!
Show more 5.2 Monitoring Airway Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society